No products in the cart.
HMGB1, as a native immunoregulator, participates in organ damage and immune rejection after transplantation and may become a marker for successful organ implantation. In mouse animal model experiments, HMGB1 antagonists may be used to increase post- survival time and decrease the expression of IL-6, interferon and HMGB1. Recently, Xia et al. have shown that HMGB1 promotes post-transplant acute rejection may be achieved by enhancing the IL-17 + CD4 T lymphocyte immune response, HMGB1 also promotes the growth of inflammatory-like dendritic cells in chronic heart rejection. The use of HMGB1 neutralizing antibodies can reduce the acute and chronic rejection of heart transplantation. However, the specific role and mechanism of HMGB1 in transplantation has not been elucidated, and further clarify the mechanism of HMGB1 in the post-transplant injury and immune rejection, which will provide a new idea for the treatment of clinical transplant injury and immune rejection.
LiJH, ZhaoB, ZhuXH, et al. Blockade of extracellular HMGB1 suppresses xenoreactive B cell responses and delays acute vascular xenogeneic rejection. Am J Transplant,2015,15(1):1–13.
This study has shown that neutralization of extracellular HMGB1 can significantly inhibit xenoreactive B cell responses and delay xenograft rejection in a rat-to-mouse model of xenotransplantation, uncovering new insights in the role of HMGB1 in transplantation.